SciSparc Ltd. (SPRC): History, Ownership, Mission, How It Works & Makes Money

SciSparc Ltd. (SPRC) is a clinical-stage pharmaceutical company, but with a market capitalization of just $1.281 million as of November 2025, is this small-cap biotech defintely a hidden gem or a high-wire act?

Their core mission is clear: developing cannabinoid-based therapies for central nervous system disorders, a strategy recently highlighted by the November 2025 filing of an Israeli patent application for a novel depression therapy through their subsidiary, NeuroThera Labs Inc., where they hold a 75% controlling interest.

Still, the financials show a complex picture, reporting a net loss of $9.33 million in the first half of 2025 against sales of only $0.461 million; so, how exactly does a company with this profile fund its ambitious pipeline of 13 patents and generate value for you as an investor?

SciSparc Ltd. (SPRC) History

SciSparc Ltd. is a clinical-stage pharmaceutical company that has undergone a complete transformation, pivoting from an early-stage immunotherapy focus to a dual strategy centered on cannabinoid-based therapies and a consumer nutraceuticals business. The company's current form is the result of a major strategic shift in 2015 and a corporate rebrand in 2021, driven by its current leadership team.

You need to understand this company's history not as a straight line, but as a sharp pivot point around 2015. That's when the core business model changed dramatically.

Given Company's Founding Timeline

Year established

The company was incorporated on August 23, 2004, under the name Therapix Biosciences Ltd..

Original location

Tel Aviv, Israel. The company remains headquartered there today.

Founding team members

While the original 2004 founders of Therapix Biosciences Ltd. are not explicitly named in public filings, the leadership team that steered the company through its critical pivot and rebrand to SciSparc Ltd. includes:

• Oz Adler, CPA: Chief Executive Officer and Chief Financial Officer (joined 2017).
• Amitai Weiss: President and Director (joined 2020).
• Dr. Adi Zuloff-Shani, PhD: Chief Technologies Officer (joined 2016).

Initial capital/funding

Initial capital is not publicly disclosed, but the first significant public funding event was the Initial Public Offering (IPO) of American Depositary Shares (ADSs) on the Nasdaq Capital Market on March 27, 2017, which raised $13.7 million.

Given Company's Evolution Milestones

Given Company's Transformative Moments

The most transformative period for SciSparc Ltd. wasn't its founding, but the strategic overhaul between 2015 and 2025. This was a survival move.

The 2015 pivot from immunotherapy to cannabinoid-based drugs was the first major decision, completely resetting the product pipeline and market focus. This is defintely the moment they bet the company on a new science.

• The 2021 Rebrand and Name Change: Changing the name from Therapix Biosciences Ltd. to SciSparc Ltd. in January 2021 solidified the new cannabinoid-focused identity, moving past the legacy of the original, less-successful business model.
• The 2022 Diversification: The acquisition of the Wellution™ brand for $4.59 million cash consideration was a crucial move to generate revenue from hemp-derived nutraceuticals, providing a commercial arm to help fund the slow, expensive clinical drug development programs.
• The 2025 Portfolio Transfer: The October 2025 agreement to transfer the advanced clinical-stage pharmaceutical portfolio to Miza III Ventures for an estimated US$11.6M valuation is the latest and most significant structural change. This move effectively separates the high-risk, high-reward pharma assets from the core SPRC entity, potentially setting up a new path for both the parent company and the spun-off assets. You can learn more about the investors who are backing this new strategy at Exploring SciSparc Ltd. (SPRC) Investor Profile: Who's Buying and Why?

Here's the quick math on the recent corporate actions: the company secured the repayment of $6.25 million in principal from the AutoMax Motors termination while simultaneously valuing its pharma portfolio at US$11.6M for the Miza III transfer, showing a clear strategy to monetize non-core assets and restructure the balance sheet in late 2025.

SciSparc Ltd. (SPRC) Ownership Structure

SciSparc Ltd.'s ownership structure is defintely unique for a Nasdaq-listed firm, demonstrating an extremely high concentration of shares in the hands of individual retail investors. This means strategic control and stock price volatility are largely dictated by the collective action of small shareholders, not large institutions or insiders.

The company is a clinical-stage pharmaceutical firm, and its governance is primarily driven by a small, experienced management team with a negligible equity stake, which is a key point for any investor to consider. You need to understand who is really steering the ship and whose capital is at risk.

SciSparc Ltd.'s Current Status

SciSparc Ltd. (SPRC) is a publicly traded company listed on the NASDAQ Capital Market under the ticker symbol SPRC. As of November 2025, the company's status is defined by its small share float following a one-for-twenty-one (1-for-21) reverse share split that became effective on July 3, 2025. This action reduced the total number of issued and outstanding ordinary shares to approximately 534,600. This low share count contributes to the stock's low institutional ownership and high retail concentration.

The stock price as of late November 2025 was trading around the $2.48 mark. For a deeper dive into the company's financial stability, you can check out Breaking Down SciSparc Ltd. (SPRC) Financial Health: Key Insights for Investors.

SciSparc Ltd.'s Ownership Breakdown

The most striking feature of SciSparc Ltd.'s ownership is the near-total dominance by retail investors, a structure that can lead to significant price swings, or what we call high volatility. Honestly, this is a retail-driven stock, plain and simple. Insider and institutional ownership is almost non-existent as a percentage of the total float.

Here's the quick math: with approximately 534,600 shares outstanding, the total institutional stake amounts to just over 7,800 shares, which is tiny. The largest single institutional holder, UBS Group Ag, holds 5,408 shares, valued at about $13.03k.

SciSparc Ltd.'s Leadership

The company is steered by a seasoned, albeit small, management team with a long average tenure, which suggests stability at the executive level, but also a lack of direct equity incentive. The average tenure for the management team is 7.6 years.

• Oz Adler, Chief Executive Officer (CEO): Mr. Adler has a long history with the company, serving as CEO since October 2022 and previously as the Director of Finance/CFO since April 2018. His total compensation for the most recent reporting period was approximately US$453.0k.
• Adi Zuloff-Shani, Chief Tech: A key figure in the company's clinical-stage development, overseeing the technological and scientific direction.
• The leadership's compensation is mostly salary-based, given the 0.00% insider ownership, so their financial incentive is tied to employment and not direct share price appreciation.

This structure means the leadership's decisions are not directly influenced by a large personal equity position, which is a structural risk you need to factor into your analysis.

SciSparc Ltd. (SPRC) Mission and Values

SciSparc Ltd.'s core mission is to develop groundbreaking, science-backed cannabinoid therapies for severe central nervous system (CNS) disorders, which ultimately drives its long-term vision of creating substantial value for patients and shareholders.

This commitment to high-risk, high-reward drug development means the company's financial performance, like the $9.33 million net loss reported for the first half of 2025, is primarily an investment in future therapeutic breakthroughs.

Given Company's Core Purpose

The company's purpose is clear: to tackle unmet medical needs using a unique cannabinoid-based platform (a drug development approach using compounds derived from cannabis). This isn't about quick profits; it's about advancing clinical-stage assets like SCI-110 for Tourette Syndrome and Alzheimer's disease agitation, which is a long and capital-intensive road.

To be fair, this focus on innovation is expensive, especially for a specialty pharmaceutical company. For instance, the sales for the first half of 2025 were only $0.461 million, reflecting a business model centered on intellectual property and clinical trial success, not high-volume product sales right now.

• Patient-Centricity: Focus on severe conditions like Tourette Syndrome and Alzheimer's agitation.
• Scientific Rigor: Leveraging an experienced team and a world-class scientific advisory board to validate cannabinoid technologies.
• Innovation: Exploring new avenues like Quantum Computing-Enabled 3D Protein Modeling for AI drug discovery, which is defintely a forward-looking strategy.

Official mission statement

While SciSparc Ltd. does not publish a single, formal mission statement quote, its consistent operational focus and public communications define its purpose as a specialty clinical-stage pharmaceutical company.

• Create and enhance a portfolio of technologies and assets based on cannabinoid pharmaceuticals.
• Develop therapies to treat disorders and rare diseases of the central nervous system (CNS).
• Advance novel, science-backed solutions for some of the world's most challenging mental health conditions through its subsidiaries and collaborations.

Vision statement

SciSparc Ltd.'s vision is to successfully commercialize its drug candidates, becoming a significant player in the CNS treatment space and, critically, to create value for its shareholders through strategic initiatives.

Here's the quick math on their strategic moves: The company's pharmaceutical assets were valued at approximately $11.6 million as part of a 2024 spin-off plan, a core action to unlock that shareholder value. The ultimate vision is to convert the promise of its clinical pipeline into tangible financial returns.

Drug development is a marathon, not a sprint.

Given Company slogan/tagline

The most concise phrase used to describe the company's offering and ambition is its focus on 'Groundbreaking Therapies.' This tagline captures the essence of their innovative, cannabinoid-based approach to complex neurological disorders.

• Groundbreaking Therapies.

If you want to dig deeper into who is betting on this vision, you should read Exploring SciSparc Ltd. (SPRC) Investor Profile: Who's Buying and Why?

SciSparc Ltd. (SPRC) How It Works

SciSparc Ltd. operates as a specialty clinical-stage pharmaceutical company, creating value by developing a portfolio of proprietary cannabinoid-based drug candidates and novel combination therapies to treat central nervous system (CNS) disorders and rare diseases.

The company makes money by advancing these drug candidates through the rigorous clinical trial process-the core asset value-plus generating immediate, albeit small, revenue from its nutraceutical arm, which sells hemp seed oil-based products on the Amazon.com Marketplace. For the half-year ended June 30, 2025, the company reported sales of USD 0.461 million, reflecting the pre-commercial stage of its primary pharmaceutical business.

SciSparc Ltd.'s Product/Service Portfolio

SciSparc's primary value lies in its advanced clinical-stage pipeline, which is focused on addressing significant unmet medical needs in neurological and psychiatric conditions. This portfolio, along with the nutraceutical business, is largely managed through its majority-owned subsidiary, NeuroThera Labs Inc., in which SciSparc holds an approximately 75% controlling interest.

SciSparc Ltd.'s Operational Framework

The company's operational model is typical for a clinical-stage biotech, centered on research and development (R&D) and intellectual property (IP) creation, not mass-market sales. Honestly, the R&D expense is where the real money goes; it was $4.87 million in 2023.

Here's the quick math on their recent cash flow situation: a terminated merger with AutoMax Motors in October 2025 means SciSparc is now a creditor, with AutoMax scheduled to repay a $2.0 million loan via $60,000 monthly installments starting November 20, 2025, plus accrued interest of $114,523 paid upfront. This repayment provides a small, defintely needed, incoming cash stream separate from drug development. You can get a deeper look at the balance sheet in Breaking Down SciSparc Ltd. (SPRC) Financial Health: Key Insights for Investors.

• R&D Focus: Directing capital toward advancing drug candidates (SCI-110, SCI-210) through FDA-mandated clinical phases.
• Subsidiary-Led Development: Utilizing NeuroThera Labs Inc. to manage the clinical portfolio and collaborations, streamlining the pharmaceutical development process.
• IP Generation: Actively filing patents, with 13 patents filed to date in collaboration with Clearmind Medicine Inc., covering combination therapies for a range of disorders including depression, alcohol use disorder, and obesity.
• Asset Monetization: Maintaining a small, operational nutraceutical business to provide a minimal revenue offset to the high R&D costs.

SciSparc Ltd.'s Strategic Advantages

SciSparc's strategic edge is built on its specialized drug platform and an aggressive push into next-generation drug discovery technologies, which positions it for potential long-term breakthroughs in difficult-to-treat CNS conditions.

• Cannabinoid Platform Specialization: Deep expertise in developing cannabinoid-based pharmaceuticals, a niche area with high regulatory barriers but significant therapeutic potential for neurological disorders.
• Advanced IP Portfolio: A growing intellectual property moat, particularly around combination therapies (e.g., MEAI and N-Acylethanolamines), which offers a path to market exclusivity for novel treatments beyond single-compound drugs.
• Quantum Computing Initiative: A forward-looking plan, announced in September 2025, to integrate quantum computing algorithms into 3D protein modeling. This aims to dramatically accelerate and improve the accuracy of drug discovery for neurological and rare diseases, potentially creating new intellectual property and reducing the time-to-market for future drug candidates.
• Clinical Trial Progress: Having drug candidates in mid-to-late-stage clinical trials (Phase IIb for Tourette Syndrome) provides a tangible, near-term asset value that can be realized upon successful completion and commercialization.

SciSparc Ltd. (SPRC) How It Makes Money

SciSparc Ltd. is a clinical-stage pharmaceutical company, meaning its core business model is not yet based on commercial drug sales but on developing a portfolio of therapies for central nervous system (CNS) disorders, primarily through its majority-owned subsidiary, NeuroThera Labs Inc.. The company makes money primarily through small, existing commercial operations, which are currently overshadowed by the significant investment in research and development (R&D), with the goal of generating future revenue from licensing agreements, milestone payments, or the eventual sale of approved drugs.

SciSparc Ltd.'s Revenue Breakdown

As a pre-commercial biotech, SciSparc Ltd.'s revenue is minimal and volatile, mainly coming from a small commercial operation or other non-core activities, and it is not yet generating revenue from its main drug candidates like Sci-110. For the half-year ended June 30, 2025, the company reported total sales of only $0.461 million.

Here's the quick math: The company's sales for the first half of 2025 were $0.461 million, which is a decrease from the $0.84 million reported in the first half of 2024, showing a clear contraction in the existing revenue stream as R&D takes priority.

Business Economics

The economic fundamentals of SciSparc Ltd. are typical of a high-risk, high-reward clinical-stage biotech. The entire business valuation rests on the success of its drug pipeline, not its current meager revenue. It's a classic 'burn rate' story right now.

• High R&D Investment: The company's cost structure is dominated by R&D expenses. In the fiscal year 2024, R&D expenses were $1.71 million, which is significantly higher than the total revenue of $1.31 million for the same period.
• Future Revenue Model: The long-term plan is to generate revenue through a value-based pricing (VBP) strategy once a drug is approved, setting the price based on its clinical efficacy and cost-effectiveness for conditions like Tourette Syndrome or Alzheimer's disease.
• Intellectual Property (IP) as an Asset: The company's true value lies in its intellectual property, which includes 13 patent applications filed through its collaboration with Clearmind Medicine Inc. for treatments targeting addiction and depression. This IP can be monetized through up-front licensing fees and sales-based royalties, which would be the first major revenue streams.
• Quantum Initiative: The launch of a quantum computing initiative for 3D protein modeling is an effort to create new intellectual property and accelerate drug discovery, which is an investment in future cost-efficiency and pipeline expansion.

The gross profit for 2024 was only $0.51 million, which barely covers a fraction of the operating expenses, so the current commercial operation is defintely not self-sustaining.

SciSparc Ltd.'s Financial Performance

The company's financial performance as of November 2025 reflects its status as a company deep in the development phase, with cash flow being the critical metric to watch, not profit.

• Net Income/Loss Volatility: For the nine months ended September 30, 2025, SciSparc Ltd. reported a net income of $1.46 million, which is a sharp shift from the net loss of $9.33 million reported for the first half of the year. This volatility often stems from one-time financial events, such as a gain on the sale of assets or a change in the fair value of warrants, rather than core operational profitability.
• Total Revenue (2024): The last full fiscal year reported total revenue of $1.31 million.
• Operating Expenses (2024): Total operating expenses for the fiscal year 2024 were $7.75 million, highlighting the significant cash burn required to fund clinical trials and R&D.
• Market Valuation: As of November 2025, the company's market capitalization is relatively small, at approximately $3.99 million, reflecting the high-risk nature and pre-commercial stage of the business.

What this estimate hides is the source of the recent Q3 2025 net income; it is crucial to analyze the cash flow statement to see if the income is sustainable or a one-off financial gain. For a deeper dive into who is betting on this model, check out Exploring SciSparc Ltd. (SPRC) Investor Profile: Who's Buying and Why?

SciSparc Ltd. (SPRC) Market Position & Future Outlook

SciSparc Ltd. is in a highly volatile transition phase, attempting to pivot from a micro-cap clinical-stage pharmaceutical company focused on Central Nervous System (CNS) disorders to a diversified entity, notably by merging into the Israeli electric vehicle (EV) sector. The company's future hinges less on its current pharmaceutical sales, which were only $\mathbf{\$0.461}$ million in the first half of 2025, and entirely on the success of its drug pipeline and the execution of its new, highly unconventional EV business strategy.

Competitive Landscape

Given its $\mathbf{\$3.9M}$ market capitalization, SciSparc operates at the fringes of the global CNS drug market, which is estimated at approximately $\mathbf{\$150}$ billion in 2025. Its direct competition comes from other small-cap biotechs with similar clinical-stage risks, not the pharmaceutical giants like Pfizer or Novartis.

SciSparc's H1 2025 sales of $\mathbf{\$0.461}$ million are a fraction of the total CNS market, making its share statistically negligible.

Opportunities & Challenges

Honestly, you're looking at a high-risk, high-reward profile here, driven by strategic pivots that are defintely outside the norm for a biotech. The biggest opportunity is the non-pharma play.

Industry Position

SciSparc's industry standing is defined by its micro-cap status and its recent, dramatic shift in corporate strategy. It's a clinical-stage company with a tiny revenue base, so its value is purely tied to pipeline milestones and the success of its new, unrelated business venture.

• Biotech Sector: Positioned as a niche player in the CNS disorder space, specifically targeting conditions like Tourette syndrome, Alzheimer's disease, and autism spectrum disorder with cannabinoid-based therapies.
• Financial Scale: With a market cap of $\mathbf{\$3.9M}$ (November 2025), it is a small-cap biotech, meaning its stock price is highly volatile and sensitive to clinical trial news.
• Diversification: The merger into the electric vehicle sector in Israel is a massive departure from its core competency, positioning it as a highly diversified, but potentially unfocused, holding company. This move is designed to capture growth outside of the high-burn, high-risk pharma world.

Here's the quick math: the company's entire market value is less than one day's revenue for a major pharmaceutical company, so every patent filing or clinical trial update is a major inflection point. For a deeper dive into the company's financial health, you should check out Breaking Down SciSparc Ltd. (SPRC) Financial Health: Key Insights for Investors.